公开(公告)号：US08163746B2

公开(公告)日：2012-04-24

申请号：US12297275

申请日：2007-04-19

申请人： Keizo Sugasawa ,  Kenichi Kawaguchi ,  Takaho Matsuzawa ,  Ryushi Seo ,  Hironori Harada ,  Akira Suga ,  Tomoaki Abe ,  Hidenori Azami ,  Shunichiro Matsumoto ,  Takashi Shin ,  Masayuki Tanahashi ,  Toru Watanabe

发明人： Keizo Sugasawa ,  Kenichi Kawaguchi ,  Takaho Matsuzawa ,  Ryushi Seo ,  Hironori Harada ,  Akira Suga ,  Tomoaki Abe ,  Hidenori Azami ,  Shunichiro Matsumoto ,  Takashi Shin ,  Masayuki Tanahashi ,  Toru Watanabe

IPC分类号： A61K31/5355 ,  A61K31/496 ,  A61K31/451 ,  A61K31/4535 ,  A61K31/426 ,  C07D413/14 ,  C07D211/32 ,  C07D211/46 ,  C07D277/24

CPC分类号： C07D277/56 ,  C07D263/34 ,  C07D263/48 ,  C07D413/04 ,  C07D413/12 ,  C07D413/14 ,  C07D417/04 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D471/10 ,  C07D487/08 ,  C07D491/08

摘要： Provided is an agent for treating or preventing urinary frequency, urinary urgency and urinary, incontinence which are associated with overactive bladder, a lower urinary tract disease such as interstitial cystitis and chronic prostatitis accompanied by lower urinary tract pain, and various diseases accompanied by pain. A novel azolecarboxamide derivative in which an azole ring such as thioazole or oxazole is bonded to a benzene ring, pyridine ring or pyrimidine ring through carboxamide was confirmed to have a potent trkA receptor-inhibitory activity and found to be an agent for treating or preventing lower urinary tract disease and various diseases accompanied by pain, which is excellent in efficacy and safety, and thus the present invention was accomplished.

摘要翻译： 提供治疗或预防与膀胱过度活动相关的尿频，尿急和尿失禁的药物，诸如间质性膀胱炎的下尿路疾病和伴有下尿路疼痛的慢性前列腺炎以及伴有疼痛的各种疾病。 通过甲酰胺将唑环或吡唑环或吡啶环或吡啶环与吡唑或恶唑等唑类结合的新型偶氮甲酰胺衍生物被证实具有强的trkA受体抑制活性，被发现是用于治疗或预防较低 泌尿道疾病，伴有疼痛的各种疾病，其功效和安全性优异，从而完成了本发明。

公开(公告)号：US20090286766A1

公开(公告)日：2009-11-19

申请号：US12297275

申请日：2007-04-19

申请人： Keizo Sugasawa ,  Kenichi Kawaguchi ,  Takaho Matsuzawa ,  Ryushi Seo ,  Hironori Harada ,  Akira Suga ,  Tomoaki Abe ,  Hidenori Azami ,  Shunichiro Matsumoto ,  Takashi Shin ,  Masayuki Tanahashi ,  Toru Watanabe

发明人： Keizo Sugasawa ,  Kenichi Kawaguchi ,  Takaho Matsuzawa ,  Ryushi Seo ,  Hironori Harada ,  Akira Suga ,  Tomoaki Abe ,  Hidenori Azami ,  Shunichiro Matsumoto ,  Takashi Shin ,  Masayuki Tanahashi ,  Toru Watanabe

IPC分类号： A61K31/496 ,  C07D417/12 ,  C07D487/04 ,  C07D417/14 ,  C07D413/12 ,  C07D413/14 ,  A61K31/454 ,  A61K31/5377 ,  A61K31/551 ,  A61K31/55 ,  A61K31/541 ,  A61P13/00

CPC分类号： C07D277/56 ,  C07D263/34 ,  C07D263/48 ,  C07D413/04 ,  C07D413/12 ,  C07D413/14 ,  C07D417/04 ,  C07D417/12 ,  C07D417/14 ,  C07D471/04 ,  C07D471/10 ,  C07D487/08 ,  C07D491/08

摘要： Provided is an agent for treating or preventing urinary frequency, urinary urgency and urinary, incontinence which are associated with overactive bladder, a lower urinary tract disease such as interstitial cystitis and chronic prostatitis accompanied by lower urinary tract pain, and various diseases accompanied by pain. A novel azolecarboxamide derivative in which an azole ring such as thioazole or oxazole is bonded to a benzene ring, pyridine ring or pyrimidine ring through carboxamide was confirmed to have a potent trkA receptor-inhibitory activity and found to be an agent for treating or preventing lower urinary tract disease and various diseases accompanied by pain, which is excellent in efficacy and safety, and thus the present invention was accomplished.

摘要翻译： 本发明提供一种治疗或预​​防尿频，尿急，尿失禁，与膀胱过度活动，下尿路疾病如间质性膀胱炎和伴有下尿路疼痛的慢性前列腺炎以及伴有疼痛的各种疾病相关的尿失禁。 通过甲酰胺将唑环或吡唑环或吡啶环或吡啶环与吡唑或恶唑等唑类结合的新型偶氮甲酰胺衍生物被证实具有强的trkA受体抑制活性，被发现是用于治疗或预防较低 泌尿道疾病，伴有疼痛的各种疾病，其功效和安全性优异，从而完成了本发明。

公开(公告)号：US08304547B2

公开(公告)日：2012-11-06

申请号：US12739433

申请日：2008-10-23

申请人： Keizo Sugasawa ,  Kenichi Kawaguchi ,  Takaho Nomura ,  Shunichiro Matsumoto ,  Takashi Shin ,  Hidenori Azami ,  Tomoaki Abe ,  Akira Suga ,  Ryushi Seo ,  Masayuki Tanahashi ,  Toru Watanabe

发明人： Keizo Sugasawa ,  Kenichi Kawaguchi ,  Takaho Nomura ,  Shunichiro Matsumoto ,  Takashi Shin ,  Hidenori Azami ,  Tomoaki Abe ,  Akira Suga ,  Ryushi Seo ,  Masayuki Tanahashi ,  Toru Watanabe

IPC分类号： C07D211/68 ,  C07D221/20 ,  C07D491/20 ,  C07D413/14 ,  C07D239/09 ,  A61K31/535 ,  A61K31/505 ,  A61K31/44 ,  A61K31/445

CPC分类号： C07D263/34 ,  C07D263/48 ,  C07D277/20 ,  C07D277/56 ,  C07D401/14 ,  C07D403/12 ,  C07D407/12 ,  C07D413/04 ,  C07D413/12 ,  C07D413/14 ,  C07D417/04 ,  C07D417/12 ,  C07D417/14 ,  C07D491/08 ,  C07D491/107 ,  C07D491/113 ,  C07D491/20 ,  C07D495/04 ,  C07D498/10

摘要： [Object] To provide a therapeutic and/or prophylactic agent for urinary frequency, urinary urgency, and urinary incontinence associated with various lower urinary tract diseases including overactive bladder, various lower urinary tract diseases accompanied by lower urinary tract pain, such as interstitial cystitis, chronic prostatitis, and the like, and various diseases accompanied by pain, based on an excellent trkA receptor inhibitory action.[Means for Solution] A novel azolecarboxamide compound in which a thiazole ring or an oxazole ring is bonded to a benzene ring, a pyridine ring, a pyridazine ring, a thiophene ring, a pyrazole ring or a pyrrole ring through carboxamide, or a salt thereof is confirmed to have a potent trkA receptor inhibitory activity, and found to be capable of being used as a therapeutic and/or prophylactic agent which is excellent in efficacy and safety for urinary frequency, urinary urgency, and urinary incontinence associated with various lower urinary tract diseases including overactive bladder, various lower urinary tract diseases accompanied by lower urinary tract pain, such as interstitial cystitis, chronic prostatitis, and the like, and various diseases accompanied by pain, thereby completing the present invention.

摘要翻译： 本发明提供一种用于与各种下尿路疾病（包括膀胱过度活动症，伴有下尿路疼痛，诸如间质性膀胱炎等）的各种下尿路疾病相关的尿频，尿急和尿失禁的治疗和/或预防剂， 慢性前列腺炎等，以及伴有疼痛的各种疾病，基于优异的trkA受体抑制作用。 [解决方案]通过甲酰胺或其盐将噻唑环或恶唑环与苯环，吡啶环，哒嗪环，噻吩环，吡唑环或吡咯环结合的新型偶氮甲酰胺化合物 被证实具有强的trkA受体抑制活性，发现能够用作治疗和/或预防剂，其对于尿频，尿急和与各种下尿路相关的尿失禁的功效和安全性优异 包括膀胱活动过度，伴有尿路下下尿路疼痛的下尿路疾病，如间质性膀胱炎，慢性前列腺炎等多种疾病，伴有疼痛的各种疾病，从而完成本发明。

公开(公告)号：US20100249088A1

公开(公告)日：2010-09-30

申请号：US12739433

申请日：2008-10-23

申请人： Keizo Sugasawa ,  Kenichi Kawaguchi ,  Takaho Nomura ,  Shunichiro Matsumoto ,  Takashi Shin ,  Hidenori Azami ,  Tomoaki Abe ,  Akira Suga ,  Ryushi Seo ,  Masayuki Tanahashi ,  Toru Watanabe

发明人： Keizo Sugasawa ,  Kenichi Kawaguchi ,  Takaho Nomura ,  Shunichiro Matsumoto ,  Takashi Shin ,  Hidenori Azami ,  Tomoaki Abe ,  Akira Suga ,  Ryushi Seo ,  Masayuki Tanahashi ,  Toru Watanabe

IPC分类号： A61K31/4545 ,  C07D413/14 ,  C07D417/14 ,  A61P13/02 ,  A61P13/10 ,  A61K31/5377 ,  A61K31/55 ,  A61K31/551 ,  A61K31/553 ,  A61K31/397 ,  A61P13/00 ,  A61P13/08

CPC分类号： C07D263/34 ,  C07D263/48 ,  C07D277/20 ,  C07D277/56 ,  C07D401/14 ,  C07D403/12 ,  C07D407/12 ,  C07D413/04 ,  C07D413/12 ,  C07D413/14 ,  C07D417/04 ,  C07D417/12 ,  C07D417/14 ,  C07D491/08 ,  C07D491/107 ,  C07D491/113 ,  C07D491/20 ,  C07D495/04 ,  C07D498/10

摘要： [Object] To provide a therapeutic and/or prophylactic agent for urinary frequency, urinary urgency, and urinary incontinence associated with various lower urinary tract diseases including overactive bladder, various lower urinary tract diseases accompanied by lower urinary tract pain, such as interstitial cystitis, chronic prostatitis, and the like, and various diseases accompanied by pain, based on an excellent trkA receptor inhibitory action.[Means for Solution] A novel azolecarboxamide compound in which a thiazole ring or an oxazole ring is bonded to a benzene ring, a pyridine ring, a pyridazine ring, a thiophene ring, a pyrazole ring or a pyrrole ring through carboxamide, or a salt thereof is confirmed to have a potent trkA receptor inhibitory activity, and found to be capable of being used as a therapeutic and/or prophylactic agent which is excellent in efficacy and safety for urinary frequency, urinary urgency, and urinary incontinence associated with various lower urinary tract diseases including overactive bladder, various lower urinary tract diseases accompanied by lower urinary tract pain, such as interstitial cystitis, chronic prostatitis, and the like, and various diseases accompanied by pain, thereby completing the present invention.

摘要翻译： 本发明提供一种用于与各种下尿路疾病（包括膀胱过度活动症，伴有下尿路疼痛，诸如间质性膀胱炎等）的各种下尿路疾病相关的尿频，尿急和尿失禁的治疗和/或预防剂， 慢性前列腺炎等，以及伴有疼痛的各种疾病，基于优异的trkA受体抑制作用。 [解决方案]通过甲酰胺或其盐将噻唑环或恶唑环与苯环，吡啶环，哒嗪环，噻吩环，吡唑环或吡咯环结合的新型偶氮甲酰胺化合物 被证实具有强的trkA受体抑制活性，发现能够用作治疗和/或预防剂，其对于尿频，尿急和与各种下尿路相关的尿失禁的功效和安全性优异 包括膀胱活动过度，伴有尿路下下尿路疼痛的下尿路疾病，如间质性膀胱炎，慢性前列腺炎等多种疾病，伴有疼痛的各种疾病，从而完成本发明。

公开(公告)号：US20110319385A1

公开(公告)日：2011-12-29

申请号：US13254368

申请日：2010-03-04

申请人： Hiroyuki Kaizawa ,  Mari Sugita ,  Hidenori Azami ,  Ryushi Seo ,  Takaho Nomura ,  Satoshi Yamamoto ,  Hirofumi Yamamoto ,  Kazuyuki Tsuchiya ,  Hideki Kubota ,  Kazunori Kamijo

发明人： Hiroyuki Kaizawa ,  Mari Sugita ,  Hidenori Azami ,  Ryushi Seo ,  Takaho Nomura ,  Satoshi Yamamoto ,  Hirofumi Yamamoto ,  Kazuyuki Tsuchiya ,  Hideki Kubota ,  Kazunori Kamijo

IPC分类号： A61K31/4985 ,  C07D413/14 ,  A61P13/00 ,  A61K31/5377 ,  A61K31/55 ,  C07D487/04 ,  C07D403/14

CPC分类号： C07D498/04 ,  C07D487/04 ,  C07D491/107 ,  C07D519/00

摘要： [Problem]Provided is a compound which has a PDE9-inhibiting action and is useful as an active ingredient for an agent for treating and/or preventing storage dysfunction, voiding dysfunction, and bladder/urethral diseases, and the like.[Means for Solution]The present inventors have investigated a compound which has a PDE9-inhibiting action and is useful as an active ingredient for an agent for treating and/or preventing storage dysfunction, voiding dysfunction, and bladder/urethral diseases, and the like, and thus, have found that an imidazoquinoxaline compound or a triazoloquinoxaline compound has a PDE9-inhibiting action, thereby completing the present invention. The imidazoquinoxaline compound or the triazoloquinoxaline compound of the present invention has a PDE9-inhibiting action and can be used as an agent for preventing and/or treating storage dysfunction, voiding dysfunction, and bladder/urethral diseases, and the like.

摘要翻译： [问题]提供具有PDE9抑制作用并可用作治疗和/或预防储存功能障碍，排尿功能障碍和膀胱/尿道疾病的药剂的活性成分的化合物等。 [解决方案]本发明人已经研究了具有PDE9抑制作用并可用作治疗和/或预防储存功能障碍，排尿功能障碍和膀胱/尿道疾病等的活性成分的化合物 ，因此已经发现咪唑并喹喔啉化合物或三唑并喹喔啉化合物具有抑制PDE9的作用，从而完成了本发明。 本发明的咪唑并喹喔啉化合物或三唑并喹喔啉化合物具有PDE9抑制作用，可用作预防和/或治疗储存功能障碍，排尿功能障碍和膀胱/尿道疾病等的药剂。

公开(公告)号：US08357688B2

公开(公告)日：2013-01-22

申请号：US13254368

申请日：2010-03-04

申请人： Hiroyuki Kaizawa ,  Mari Sugita ,  Hidenori Azami ,  Ryushi Seo ,  Takaho Nomura ,  Satoshi Yamamoto ,  Hirofumi Yamamoto ,  Kazuyuki Tsuchiya ,  Hideki Kubota ,  Kazunori Kamijo

发明人： Hiroyuki Kaizawa ,  Mari Sugita ,  Hidenori Azami ,  Ryushi Seo ,  Takaho Nomura ,  Satoshi Yamamoto ,  Hirofumi Yamamoto ,  Kazuyuki Tsuchiya ,  Hideki Kubota ,  Kazunori Kamijo

IPC分类号： A61K31/495

CPC分类号： C07D498/04 ,  C07D487/04 ,  C07D491/107 ,  C07D519/00

摘要： Substituted imidazo[1,5-a]quinoxalin-4(5H)-ones are useful as PDE9 inhibitors.

摘要翻译： 取代的咪唑并[1,5-a]喹喔啉-4（5H） - 酮可用作PDE9抑制剂。

公开(公告)号：US20090312328A1

公开(公告)日：2009-12-17

申请号：US12297445

申请日：2007-08-09

申请人： Hideki Kubota ,  Susumu Toda ,  Issei Tsukamoto ,  Yuta Fukuda ,  Ryutaro Wakayama ,  Kazuki Ono ,  Toru Watanabe ,  Hidenori Azami

发明人： Hideki Kubota ,  Susumu Toda ,  Issei Tsukamoto ,  Yuta Fukuda ,  Ryutaro Wakayama ,  Kazuki Ono ,  Toru Watanabe ,  Hidenori Azami

IPC分类号： A61K31/18 ,  C07C311/21 ,  C07D213/56 ,  C07D239/26 ,  C07D295/155 ,  C07D241/08 ,  A61K31/222 ,  A61K31/195 ,  A61K31/44 ,  A61K31/4406 ,  A61K31/505 ,  A61K31/4965 ,  A61K31/5375 ,  A61P13/00

CPC分类号： C07C311/29 ,  A61K31/18 ,  A61K31/195 ,  A61K31/197 ,  A61K31/198 ,  A61K31/216 ,  A61K31/235 ,  A61K31/24 ,  A61K31/275 ,  A61K31/341 ,  A61K31/343 ,  A61K31/381 ,  A61K31/40 ,  A61K31/4015 ,  A61K31/404 ,  A61K31/415 ,  A61K31/4196 ,  A61K31/423 ,  A61K31/426 ,  A61K31/44 ,  A61K31/4402 ,  A61K31/4406 ,  C07C311/14 ,  C07C311/19 ,  C07C311/21 ,  C07C311/47 ,  C07C311/51 ,  C07C323/49 ,  C07C2601/02 ,  C07C2601/08 ,  C07C2601/14 ,  C07C2602/08 ,  C07C2602/10 ,  C07D207/27 ,  C07D207/325 ,  C07D209/08 ,  C07D213/40 ,  C07D213/68 ,  C07D213/70 ,  C07D213/79 ,  C07D213/89 ,  C07D215/12 ,  C07D217/06 ,  C07D231/12 ,  C07D237/08 ,  C07D239/26 ,  C07D241/12 ,  C07D249/08 ,  C07D263/32 ,  C07D263/58 ,  C07D277/20 ,  C07D277/28 ,  C07D277/36 ,  C07D295/12 ,  C07D307/52 ,  C07D307/81 ,  C07D333/20 ,  C07D333/34 ,  C07D333/38 ,  C07D333/40 ,  C07D333/58

摘要： [Object] A compound that can be used as an agent for treating a disease associated with an EP1 receptor, in particular, a lower urinary tract symptom.[Means for Solution] It was confirmed that a sulfonamide compound having an amide structure and characterized by a chemical structure in which a carbon atom in the amide bonds to the N atom in sulfonamide through lower alkylene, or a salt thereof, has a potent EP1 receptor antagonistic activity, accomplishing the present invention. Since the sulfonamide compound of the present invention or a pharmaceutically acceptable salt thereof has a potent EP1 receptor antagonistic activity, it is useful as an agent for treating a disease associated with an EP1 receptor, in particular, a lower urinary tract symptom.

摘要翻译： [对象]可用作治疗与EP1受体，特别是下尿路症状相关的疾病的药剂的化合物。 [溶液的方法]确认具有酰胺结构的磺酰胺化合物，其特征在于其中酰胺中的氨基与磺酰胺中的N原子通过低级亚烷基或其盐键合的化学结构具有有效的EP1 受体拮抗活性，完成本发明。 由于本发明的磺酰胺化合物或其药学上可接受的盐具有有效的EP1受体拮抗活性，因此可用作治疗与EP1受体，特别是下尿路症状相关的疾病的药剂。

公开(公告)号：US07973078B2

公开(公告)日：2011-07-05

申请号：US12297445

申请日：2007-08-09

申请人： Hideki Kubota ,  Susumu Toda ,  Issei Tsukamoto ,  Yuta Fukuda ,  Ryutaro Wakayama ,  Kazuki Ono ,  Toru Watanabe ,  Hidenori Azami

发明人： Hideki Kubota ,  Susumu Toda ,  Issei Tsukamoto ,  Yuta Fukuda ,  Ryutaro Wakayama ,  Kazuki Ono ,  Toru Watanabe ,  Hidenori Azami

IPC分类号： C07C303/00 ,  A01N41/06

CPC分类号： C07C311/29 ,  A61K31/18 ,  A61K31/195 ,  A61K31/197 ,  A61K31/198 ,  A61K31/216 ,  A61K31/235 ,  A61K31/24 ,  A61K31/275 ,  A61K31/341 ,  A61K31/343 ,  A61K31/381 ,  A61K31/40 ,  A61K31/4015 ,  A61K31/404 ,  A61K31/415 ,  A61K31/4196 ,  A61K31/423 ,  A61K31/426 ,  A61K31/44 ,  A61K31/4402 ,  A61K31/4406 ,  C07C311/14 ,  C07C311/19 ,  C07C311/21 ,  C07C311/47 ,  C07C311/51 ,  C07C323/49 ,  C07C2601/02 ,  C07C2601/08 ,  C07C2601/14 ,  C07C2602/08 ,  C07C2602/10 ,  C07D207/27 ,  C07D207/325 ,  C07D209/08 ,  C07D213/40 ,  C07D213/68 ,  C07D213/70 ,  C07D213/79 ,  C07D213/89 ,  C07D215/12 ,  C07D217/06 ,  C07D231/12 ,  C07D237/08 ,  C07D239/26 ,  C07D241/12 ,  C07D249/08 ,  C07D263/32 ,  C07D263/58 ,  C07D277/20 ,  C07D277/28 ,  C07D277/36 ,  C07D295/12 ,  C07D307/52 ,  C07D307/81 ,  C07D333/20 ,  C07D333/34 ,  C07D333/38 ,  C07D333/40 ,  C07D333/58

摘要： A compound that can be used as an agent for treating a disease associated with an EP1 receptor, in particular a lower urinary tract symptom. It was confirmed that a sulfonamide compound having an amide structure and characterized by a chemical structure in which a carbon atom in the amide bonds to the N atom in sulfonamide through lower alkylene, or a salt thereof, has a potent EP1 receptor antagonistic activity, accomplishing the present invention. Since the sulfonamide compound of the present invention or a pharmaceutically acceptable salt thereof has a potent EP1 receptor antagonistic activity, it is useful as an agent for treating a disease associated with an EP1 receptor, in particular, a lower urinary tract symptom.

摘要翻译： 可用作治疗与EP1受体相关疾病，特别是下尿路症状的药物的化合物。 证实具有酰胺结构的磺酰胺化合物，其特征在于其中酰胺中的碳原子与磺酰胺中的N原子通过低级亚烷基或其盐键合的化学结构具有有效的EP1受体拮抗活性，完成 本发明。 由于本发明的磺酰胺化合物或其药学上可接受的盐具有有效的EP1受体拮抗活性，因此可用作治疗与EP1受体，特别是下尿路症状相关的疾病的药剂。

公开(公告)号：US20070123532A1

公开(公告)日：2007-05-31

申请号：US11562149

申请日：2006-11-21

申请人： Kazuhiko Take ,  Nobukiyo Konishi ,  Shinji Shigenaga ,  Natsuko Kayakiri ,  Hidenori Azami ,  Yoshiteru Eikyu ,  Kazuo Nakai ,  Junya Ishida ,  Masataka Morita

发明人： Kazuhiko Take ,  Nobukiyo Konishi ,  Shinji Shigenaga ,  Natsuko Kayakiri ,  Hidenori Azami ,  Yoshiteru Eikyu ,  Kazuo Nakai ,  Junya Ishida ,  Masataka Morita

IPC分类号： A61K31/5377 ,  A61K31/496

CPC分类号： C07D401/06 ,  C07D241/04 ,  C07D401/14 ,  C07D403/06 ,  C07D403/14 ,  C07D413/06 ,  C07D413/14 ,  C07D417/06 ,  C07D471/04 ,  C07D491/08 ,  C07D495/04 ,  C07D498/04 ,  C07D498/08 ,  C07F7/1804

摘要： This invention relates to piperazine derivatives of the formula: wherein each symbol is as defined in the description, and its pharmaceutically acceptable salt, to processes for preparation thereof, to pharmaceutical composition comprising the same, and to a use of the same for treating or preventing Tachykinin-mediated diseases in human being or animals.

摘要翻译： 本发明涉及下式的哌嗪衍生物：其中每个符号如说明书中所定义，及其药学上可接受的盐，其制备方法，包含其的药物组合物及其用于治疗或预防的用途 速激肽介导的人类或动物疾病。

公开(公告)号：US08314240B2

公开(公告)日：2012-11-20

申请号：US13000677

申请日：2009-06-22

申请人： Hideki Kubota ,  Issei Tsukamoto ,  Kazunori Kamijo ,  Koji Kato ,  Yuta Fukuda ,  Hidenori Azami

发明人： Hideki Kubota ,  Issei Tsukamoto ,  Kazunori Kamijo ,  Koji Kato ,  Yuta Fukuda ,  Hidenori Azami

IPC分类号： A61K31/44 ,  C07D213/62

CPC分类号： C07C311/21 ,  A61K31/341 ,  A61K31/426 ,  A61K31/427 ,  A61K31/4402 ,  A61K31/4406 ,  A61K31/443 ,  A61K31/4439 ,  A61K31/497 ,  A61K31/501 ,  A61K31/506 ,  C07C2602/08 ,  C07D213/71 ,  C07D213/80 ,  C07D277/20 ,  C07D277/36 ,  C07D277/56 ,  C07D307/64 ,  C07D401/12 ,  C07D403/12 ,  C07D405/12 ,  C07D417/12

摘要： [Object] A compound which is useful as an EP1 receptor antagonist is provided.[Means for Solution] The present inventors investigated EP1 receptor antagonists, and confirmed that a compound having a sulfonamide structure, in which the nitrogen atom of the sulfonamide structure is substituted with 2-fluoropropyl group, 3-fluoro-2-methylpropyl group or the like, has a potent EP1 receptor antagonistic action, thereby completing the present invention. The sulfonamide compound of the present invention has a potent EP1 receptor antagonistic action and can be used as an agent for preventing and/or treating a lower urinary tract symptom or the like.

摘要翻译： 提供了可用作EP1受体拮抗剂的化合物。 [解决方案]本发明人研究了EP1受体拮抗剂，并证实了具有磺酰胺结构的化合物，其中磺酰胺结构的氮原子被2-氟丙基取代，3-氟-2-甲基丙基或 具有有效的EP1受体拮抗作用，从而完成本发明。 本发明的磺酰胺化合物具有有效的EP1受体拮抗作用，可用作预防和/或治疗下尿路症状等的药剂。